ATLAS Biolabs GmbH Joins Roche NimbleGen’s Certified Service Provider Program for Targeted Enrichment
News Feb 03, 2010
They will provide services for NimbleGen 454 Optimized Sequence Capture Arrays coupled with sequencing services on the Genome Sequencer FLX System from 454 Life Sciences, a Roche Company. ATLAS Biolabs GmbH has passed a rigorous certification test plan to achieve precise experimental standards to officially join the Roche NimbleGen Certified Service Provider Program. Their certification marks the second genomic service provider to join the Roche NimbleGen CSP Program for Sequence Capture in Europe. They will process customer gDNA samples for genomic enrichment, using the complete NimbleGen Sequence Capture workflow optimized for 454 GS FLX Titanium Series sequencing using 385K Arrays (capture of up to 5 Mb custom regions) and 2.1M Array (Human Exome and capture of up to 30 Mb custom regions).
“The decision to join the Roche NimbleGen CSP Program was a logical extension of our portfolio. Our customers are looking at targeted genomic sequencing and we wanted to provide them with a set of elite solutions for the necessary enrichment” said Prof. Dr. Peter Nurnberg, CEO of ATLAS Biolabs GmbH.
“Roche NimbleGen welcomes the latest addition, ATLAS Biolabs GmbH, to our CSP family for Sequence Capture. ATLAS Biolab’s close ties with key opinion leaders across several key market segments in Germany, in addition to their established academic excellence, will further strengthen our position as a leader in the targeted resequencing market and drive future growth of the Roche NimbleGen business and service channel in Europe," said Jay Schiestle, Vice President of Manufacturing for Roche NimbleGen, Inc.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.